Lorantis: creating new medicines for selective treatment of immunological diseases

Abstract Lorantis is discovering and developing novel products for the treatment of immunological and inflammatory diseases based on the emerging field of antigen-specific tolerance. The company's products are derived from the discovery of a new set of biochemical signalling pathways that regulate the action of T cells. These discoveries will enable Lorantis to build a portfolio of novel drugs with the ability to treat selectively a wide range of disorders, including allergy, asthma, autoimmune diseases and transplant rejection.